[Lipid profile in the hyperacute phase of ischemic stroke allows to decide cholesterol-lowering therapy].
OBJECTIVE
We aimed to determine whether measuring the hyperacute lipid profile helps to start a cholesterol-lowering therapy soon after an ischemic stroke.


METHODS
72 ischemic stroke patients underwent lipid determinations at three times (hyperacute phase or arrival, second day and the third month).


RESULTS
Total cholesterol, cLDL, cHDL and triglyceride mean values were significantly higher (p < 0.05) at arrival compared to the second day (212 vs 189; 131 vs 120; 52 vs 44 and 132 vs 115, respectively). In the third month, mean values were similar to those of the hyperacute phase (197, 131, 48 and 143, respectively). Considering the updated cholesterol management guidelines, we should treat 55% of patients diagnosed at the hyperacute phase but only 37% of patients diagnosed at the second day.


CONCLUSIONS
Hyperacute lipid profile determination helps to determine those patients who need a cholesterol-lowering therapy without delay.
Delgado Martínez
Pilar
P
Servicio de Neurología, Hospital Universitario de la Vall d'Hebron, Barcelona, Spain. pdm@comb.es
Montaner Villalonga
Joan
J
Chacón
Pilar
P
Purro
Francisco
F
Ribó
Marc
M
Alvarez-Sabín
José
J
D000208:Acute Disease; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000097:blood* / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D020521:Stroke / Q000097:blood* / Q000188:drug therapy*; D013997:Time Factors; D014280:Triglycerides / Q000097:blood*
D000924:Anticholesteremic Agents; D014280:Triglycerides; D002784:Cholesterol